Here are several interesting multiple myeloma research studies/articles which have crossed my desk recently:
Mayo Clinic-TGen Study Discovers Role of DNA Methylation in Multiple Myeloma
Report Finds Development of Multiple Myeloma is Tied to ‘Hypomethylation’
PHOENIX — DNA methylation — a modification of DNA linked to gene regulation — is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).
And at specific points of DNA, “global hypomethylation,” in which many genes lose the modification, may be associated with the step-by-step development of myeloma, according to a scientific paper published this month in the journal Cancer Research.
“This is the first study to show that hypomethylation occurs early in the development of multiple myeloma and increases through disease progression,” said Dr. Bodour Salhia, a TGen cancer researcher and the paper’s lead author.
DNA methylation suppresses the expression of viral genes and other harmful elements incorporated over time into an individual’s genome. In cancer, hypermethylation at certain genomic locations can turn tumor suppressing genes off, while hypomethylation in some instances may lead to the over-expression of oncogenes, or those genes that give rise to cancer, and is linked to chromosomal instability.
Read more by going to: Centredaily.com/Mayo Clinic TGen Study.
The next research paper alerts primary care physicians and post stem cell transplant patients to the risk of complications which may emerge many months following a SCT:
Late Complications in Blood and Marrow Transplant Survivors
By Navneet S. Majhail, M.D., M.S.
Hematopoietic stem-cell transplantation is a potentially curative therapy for many high-risk hematologic malignancies and other life-threatening disorders. Advances in transplantation over the last four decades have resulted in an increasing number of long-term survivors who may be at risk for developing late infections, noninfectious complications, and secondary cancers. Awareness on the part of primary care physicians of the risk factors and screening recommendations for late complications can lead to their early diagnosis and treatment.
The Primary Care Physician’s Role
During the first few months following transplantation, HSCT recipients receive the vast majority of their medical care at the transplant center. Over time, their care is transitioned to their referring hematologist-oncologist. Eventually, most long-term survivors of HSCT who do not have ongoing transplant-related complications (eg, chronic GVHD) receive medical care through their primary care physician.23 As transplant centers get stretched to their capacity to accommodate the increasing number of patients who need HSCT, primary care physicians will play an even greater role in the long-term care of HSCT survivors and will need to be aware of the unique exposures, risk factors, and medical issues that these patients face.
When caring for a patient who has undergone HSCT, it is important to construct a risk profile, taking into account the patient’s age, gender, coexisting comorbidities, cancer, transplant-related exposures, and post-treatment complications. With the help of expert consensus guidelines and recommendations (Table 4),22,24,25 primary care physicians can do this and focus on preventing and screening for specific complications for which a particular patient may be at risk.
This study features some worthwhile content for post SCT patients. Go to:
MinnesotaMedicine.com/Late Complications to read more.
Feel good and keep smiling! Pat